SCHEMBL2865693

SCHEMBL2865693

NCCN(CC1CC1)S(=O)(=O)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.46
MEN1 O00255 3/20 0.46
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR7 P34969 1/20 0.43
ACHE P22303 1/20 0.42
NPC1 O15118 1/20 0.42
PTPN1 P18031 1/20 0.42
ALDH1A1 P00352 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
NPY1R P25929 2/20 0.41
NPY5R Q15761 2/20 0.41
DRD2 P14416 1/20 0.41
ADRA2C P18825 1/20 0.41
F2 P00734 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13136199 0.82 THRB (0.46) KMT2AMEN1HTR2AHTR2CHTR7
SCHEMBL16154331 0.80 VCAM1 (0.51) KMT2AMEN1PTPN1ALDH1A1F2
SCHEMBL2858460 0.79 KMT2A (0.48) KMT2AMEN1ACHENPC1ALDH1A1
SCHEMBL2861721 0.78 KMT2A (0.47) KMT2AMEN1PTPN1ALDH1A1F2
SCHEMBL6775989 0.78 TAS2R14 (0.48) KMT2AMEN1NPC1PTPN1ALDH1A1
SCHEMBL1984721 0.77 KMT2A (0.51) KMT2AMEN1PTPN1F2PRSS1
SCHEMBL4362944 0.76 KMT2A (0.54) KMT2AMEN1ALDH1A1NPY5RF2
SCHEMBL1026059 0.75 KMT2A (0.68) KMT2AMEN1ALDH1A1F2PRSS1
SCHEMBL20269611 0.75 ALDH1A1 (0.44) KMT2AMEN1PTPN1ALDH1A1NPY1R
SCHEMBL16379309 0.75 KMT2A (0.49) KMT2AMEN1ACHEPTPN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 KMT2A 922/4885MEN1 4666/4885HTR2A 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.